Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies
- PMID: 35526614
- DOI: 10.1016/j.jconrel.2022.05.001
Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies
Abstract
Glaucoma is an optic neuropathy disorder marked by progressive degeneration of the retinal ganglion cells (RGC). It is a leading cause of blindness worldwide, prevailing in around 2.2% of the global population. The hallmark of glaucoma, intraocular pressure (IOP), is governed by the aqueous humor dynamics which plays a crucial role in the pathophysiology of the diesease. Glaucomatous eye has an IOP of more than 22 mmHg as compared to normotensive pressure of 10-21 mmHg. Currently used treatments focus on reducing the elevated IOP through use of classes of drugs that either increase aqueous humor outflow and/or decrease its production. However, effective treatments should not only reduce IOP, but also offer neuroprotection and regeneration of RGCs. Hydrogen Sulfide (H2S), a gasotransmitter with several endogenous functions in mammalian tissues, is being investigated for its potential application in glaucoma. In addition to decreasing IOP by increasing aqueous humor outflow, it scavenges reactive oxygen species, upregulates the cellular antioxidant glutathione and protects RGCs from excitotoxicity. Despite the potential of H2S in glaucoma, its delivery to anterior and posterior regions of the eye is a challenge due to its unique physicochemical properties. Firstly, development of any delivery system should not require an aqueous environment since many H2S donors are susceptible to burst release of the gas in contact with water, causing potential toxicity and adverse effects owing to its inherent toxicity at higher concentrations. Secondly, the release of the gas from the donor needs to be sustained for a prolonged period of time to reduce dosing frequency as per the requirements of regulatory bodies. Lastly, the delivery system should provide adequate bioavailability throughout its period of application. Hence, an ideal delivery system should aim to tackle all the above challenges related to barriers of ocular delivery and physicochemical properties of H2S itself. This review discusses the therapeutic potential of H2S, its delivery challenges and strategies to overcome the associated chalenges.
Keywords: Drug delivery; Glaucoma; Hydrogen sulfide; Intraocular pressure; Neuroprotection; Sustained release.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Exogenous hydrogen sulfide and NOX2 inhibition mitigate ferroptosis in pressure-induced retinal ganglion cell damage.Biochim Biophys Acta Mol Basis Dis. 2025 Mar;1871(3):167705. doi: 10.1016/j.bbadis.2025.167705. Epub 2025 Feb 4. Biochim Biophys Acta Mol Basis Dis. 2025. PMID: 39914725
-
Regulation of Aqueous Humor Dynamics by Hydrogen Sulfide: Potential Role in Glaucoma Pharmacotherapy.J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):61-69. doi: 10.1089/jop.2017.0077. Epub 2017 Dec 7. J Ocul Pharmacol Ther. 2018. PMID: 29215951 Free PMC article. Review.
-
Relevant variations and neuroprotecive effect of hydrogen sulfide in a rat glaucoma model.Neuroscience. 2017 Jan 26;341:27-41. doi: 10.1016/j.neuroscience.2016.11.019. Epub 2016 Nov 24. Neuroscience. 2017. PMID: 27890826
-
Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo.Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5129-5141. doi: 10.1167/iovs.17-22200. Invest Ophthalmol Vis Sci. 2017. PMID: 28986598
-
Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.Eur J Pharm Biopharm. 2015 Sep;95(Pt B):182-93. doi: 10.1016/j.ejpb.2015.01.031. Epub 2015 Feb 9. Eur J Pharm Biopharm. 2015. PMID: 25676338 Review.
Cited by
-
Cyclodextrin Metal-Organic Framework as a Broad-Spectrum Potential Delivery Vehicle for the Gasotransmitters.Molecules. 2023 Jan 14;28(2):852. doi: 10.3390/molecules28020852. Molecules. 2023. PMID: 36677910 Free PMC article.
-
Comparison of colorimetric, spectroscopic and electrochemical techniques for quantification of hydrogen sulfide.Biotechniques. 2024 Feb;76(2):71-80. doi: 10.2144/btn-2023-0075. Epub 2023 Dec 7. Biotechniques. 2024. PMID: 38059376 Free PMC article.
-
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H2S Donors.Int J Mol Sci. 2022 Nov 9;23(22):13804. doi: 10.3390/ijms232213804. Int J Mol Sci. 2022. PMID: 36430281 Free PMC article.
-
Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.Pharmaceutics. 2023 Mar 3;15(3):837. doi: 10.3390/pharmaceutics15030837. Pharmaceutics. 2023. PMID: 36986699 Free PMC article. Review.
-
Aqueous Proteomic and Metabolomic Profiles in Low-Energy vs High-Energy Femtosecond Laser-Assisted Cataract Surgery.Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):10. doi: 10.1167/iovs.66.1.10. Invest Ophthalmol Vis Sci. 2025. PMID: 39775700 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical